MedPharm and Palvella Therapeutics have been named finalists in the True Partnership Excellence category at the CPHI Awards 2026, recognizing their multi-year collaboration in the development of QTORIN™ rapamycin.
MedPharm and Palvella Therapeutics have been named finalists in the True Partnership Excellence category at the CPHI Awards 2026, recognizing their multi-year collaboration in the development of QTORIN™ rapamycin.